Urolithin A

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Urolithin A
DrugBank Accession Number
DB15464
Background

Urolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.1

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 228.2002
Monoisotopic: 228.042258744
Chemical Formula
C13H8O4
Synonyms
  • 3,8-Dihydroxyurolithin
  • 3,8-Hydroxydibenzo-alpha-pyrone

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one).
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Not Available
Direct Parent
Coumarins and derivatives
Alternative Parents
Isocoumarins and derivatives / 2-benzopyrans / 1-benzopyrans / Pyranones and derivatives / 1-hydroxy-2-unsubstituted benzenoids / Heteroaromatic compounds / Lactones / Oxacyclic compounds / Organooxygen compounds / Organic oxides
show 1 more
Substituents
1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 2-benzopyran / Aromatic heteropolycyclic compound / Benzenoid / Benzopyran / Coumarin / Heteroaromatic compound / Hydrocarbon derivative / Isocoumarin
show 8 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
ILJ8NEF6DT
CAS number
1143-70-0
InChI Key
RIUPLDUFZCXCHM-UHFFFAOYSA-N
InChI
InChI=1S/C13H8O4/c14-7-1-3-9-10-4-2-8(15)6-12(10)17-13(16)11(9)5-7/h1-6,14-15H
IUPAC Name
3,8-dihydroxy-6H-benzo[c]chromen-6-one
SMILES
OC1=CC2=C(C=C1)C1=C(C=C(O)C=C1)C(=O)O2

References

General References
  1. Pénélope A. Andreux, William Blanco-Bose, Dongryeol Ryu, Frédéric Burdet, Mark Ibberson, Patrick Aebischer, Johan Auwerx, Anurag Singh & Chris Rinsch: The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans Nature Metabolism. 2019 June 14;1:595–603. [Article]
Human Metabolome Database
HMDB0013695
ChemSpider
4589709
ChEMBL
CHEMBL1836264
ZINC
ZINC000013484727
Wikipedia
Urolithin_A

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.263 mg/mLALOGPS
logP2.16ALOGPS
logP2.32Chemaxon
logS-2.9ALOGPS
pKa (Strongest Acidic)7.21Chemaxon
pKa (Strongest Basic)-7.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area66.76 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity60.9 m3·mol-1Chemaxon
Polarizability22.26 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0fai-0980000000-794e7711dd60a731dd65
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0090000000-acfb75f1798234e09d48
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0090000000-f3e3b44cfd390e3fa779
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0090000000-0b867431d9cd5583458b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004j-0490000000-b70959313bf113603b50
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pbi-0920000000-79ee9d733167ff879dc8
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-006t-0900000000-9c517a9faf3fe6405382
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-155.5515212
predicted
DarkChem Lite v0.1.0
[M-H]-155.7609212
predicted
DarkChem Lite v0.1.0
[M-H]-155.8440212
predicted
DarkChem Lite v0.1.0
[M-H]-150.7924
predicted
DeepCCS 1.0 (2019)
[M+H]+157.6601212
predicted
DarkChem Lite v0.1.0
[M+H]+158.3509212
predicted
DarkChem Lite v0.1.0
[M+H]+159.0381212
predicted
DarkChem Lite v0.1.0
[M+H]+153.1504
predicted
DeepCCS 1.0 (2019)
[M+Na]+156.9560212
predicted
DarkChem Lite v0.1.0
[M+Na]+157.1069212
predicted
DarkChem Lite v0.1.0
[M+Na]+156.8659212
predicted
DarkChem Lite v0.1.0
[M+Na]+159.24355
predicted
DeepCCS 1.0 (2019)

Drug created at June 18, 2019 22:52 / Updated at June 12, 2020 16:53